Feature | June 13, 2014

Molecular Imaging Finds Novel Way to Knock Down Breast Cancer

Antibody-based molecular imaging agent hones in on newly targeted cell receptor that hints at more aggressive breast cancers and potential therapy

June 13, 2014 – For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells — specifically those testing positive for human epidermal growth factor receptor 2 (HER2). A recent innovation in breast cancer biomarkers seeks the HER3 receptor instead, which could mean more comprehensive breast cancer imaging and potential treatments, say experts presenting data during the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI).

Breast cancer is one of the most prevalent forms of cancer among women. Certain kinds of tumors have been found to be more aggressive and associated with less than favorable prognoses compared to others. HER2 positive tumors are a hallmark of high-risk breast cancer. Emerging molecular imaging agents join tumor-seeking antibodies and signaling radioisotopes in one radiopharmaceutical that is injected at the time of imaging in order to track and report active receptors.

One of these investigational agents, known in the lab as Cu-64 DOTA-HER3 F(ab')2, does just that by hunting down HER3, a messenger that has been shown to speak for HER2-positive cancers in multiple tissue models when used in conjunction with a scanner called a positron emission tomography (PET) imaging system. This could encourage better, more personalized care for breast cancer patients.

“HER3 is thought to be an important mediator of resistance to the HER2 inhibitors class of anti-cancer therapies, which are used to treat HER2-positive breast cancer representing approximately 20 percent of all breast cancers,” said principal author Eric P. Wehrenberg-Klee, M.D., from Massachusetts General Hospital in Boston, Mass. “Imaging of HER3 expression may allow for better understanding of how prevalent HER3 over-expression is among HER2 positive breast cancer patients, which in turn may allow for appropriate patient selection for the addition of HER3 inhibitors currently in clinical development.”

The researchers expect that it may be another year or two before the agent will reach regulatory approval and enter general clinical practice.

For more information: www.snmmi.org

Related Content

Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading
News | Computer-Aided Detection Software | January 12, 2018
Deep learning and artificial intelligence improves the efficiency and accuracy of reading mammograms, according to...
Fat Distribution in Women and Men Provides Clues to Heart Attack Risk
News | Women's Health | January 11, 2018
January 11, 2018 – It’s not the amount of fat in your body but where it is stored that may increase your risk for hea
Women Prefer Getting Mammograms Every Year
News | Mammography | January 09, 2018
Women prefer to get their mammograms every year, instead of every two years, according to a new study presented at the...
Planmed Clarity 2-D Digital Mammography System Receives FDA Approval
Technology | Mammography | January 08, 2018
The U.S. Food and Drug Administration (FDA) issued an approval letter for the Planmed Clarity 2-D full-field digital...
Overweight Women May Need More Frequent Mammograms
News | Mammography | January 04, 2018
Women with higher body mass index (BMI) face an increased risk of not detecting their breast tumor until it has become...
About 25 percent of screening patients and 60 percent of diagnostic patients do not have prior mammograms available for comparison at the time of their examinations due to the lack of interoperability or other restrictions preventing clinicians from accessing prior exams.

About 25 percent of screening patients and 60 percent of diagnostic patients do not have prior mammograms available for comparison at the time of their examinations due to the lack of interoperability or other restrictions preventing clinicians from accessing prior exams.

Feature | Breast Imaging | January 02, 2018 | Kathryn Pearson Peyton, M.D.
Sixty million women undergo regular screening mammography in the United States, but even in the digital age, it is di
Imagio Opto-Acoustic Breast Imaging System Helps Differentiate Tumor Subtypes
News | Oncology Diagnostics | January 02, 2018
Seno Medical Instruments Inc. (Seno Medical) recently reported data from their clinical study demonstrating that its...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init